Nuclear Medicine Radioisotopes Market 2024-2032:

  • The global nuclear medicine radioisotopes market size reached USD 7.3 Billion in 2023.
  • The market is expected to reach USD 14.2 Billion by 2032, exhibiting a growth rate (CAGR) of 7.51% during 2024-2032.
  • North America leads the market, accounting for the largest nuclear medicine radioisotopes market share.
  • Diagnostics (technetium-99m (Tc-99m) accounts for the majority of the market share in the product segment due to its extensive application in single photon emission computed tomography (SPECT) imaging. 
  • Cardiology holds the largest share in the nuclear medicine radioisotopes industry, as nuclear medicine radioisotopes help to assess blood flow, heart function, and detect coronary artery disease.
  • Based on the end user, the market has been divided into hospitals, diagnostic centers, specialty clinics, education and research institutes, and others.
  • The rising prevalence of cancer cases across the globe is a primary driver of the nuclear medicine radioisotopes market.
  • Technological advancements and the introduction hybrid imaging systems are reshaping the nuclear medicine radioisotopes market.

Request for a sample copy of this report: https://www.imarcgroup.com/nuclear-medicine-radioisotopes-market/requestsample

Industry Trends and Drivers:

  • Rising Prevalence of Cancer and Cardiovascular Diseases:

The increasing burden of cancer and cardiovascular diseases across the globe is one of the major factors boosting the nuclear medicine radioisotopes market share. They play a crucial role in the diagnosis and treatment of various cancers. Moreover, the extensive utilization of radiopharmaceuticals, which contain these isotopes, in imaging techniques like positron emission tomography (PET) and single photon emission computed tomography (SPECT) to detect tumors at early stages is enhancing the market growth. Additionally, the widespread employment of therapeutic radioisotopes to target cancer cells more precisely, thus minimizing damage to surrounding healthy tissue, is providing a considerable boost to the market growth.

  • Rapid Advancements in Nuclear Medicine Technology:

The rapid technological innovations in nuclear medicine, leading to improved precision and effectiveness of radioisotopes, are boosting the nuclear medicine radioisotopes market size. Moreover, rapid innovations such as hybrid imaging systems, including PET-CT and SPECT-CT, that revolutionize diagnostic capabilities by providing more detailed images and enabling earlier detection of diseases are fueling the market growth. Apart from this, the development of new radioisotopes that offer better imaging contrast and therapeutic efficacy is also contributing to the market growth. Additionally, the growing research on novel radiopharmaceuticals, including theranostics, which combine diagnostics and therapy in one process, is acting as a growth-inducing factor.

  • Increasing Government and Private Sector Investments:

The growing recognition among governments and private organizations across the globe of the potential of nuclear medicine in improving healthcare outcomes is positively influencing the market growth. Additionally, the nuclear medicine radioisotopes market trends indicate that the increasing investment in infrastructure by countries to support the production and distribution of medical isotopes is supporting the market growth. For example, several national health organizations are establishing partnerships with private companies to develop and expand isotope production facilities. Additionally, the growing focus on public funding that is directed toward research and development (R&D) in nuclear medicine, such as cancer treatment, neurological disorders, and cardiovascular diseases, is anticipated to drive the market growth.

Nuclear Medicine Radioisotopes Market Report Segmentation:

Breakup By Product:

  • Diagnostics
    • Technetium-99m (Tc-99m)
    • Gallium-67
    • Thallium-201
    • Fluorine-18
    • Others
  • Therapeutics
    • Rhenium-186
    • Iodine-131
    • Samarium-153
    • Yttrium-90
    • Others

Diagnostics (technetium-99m (Tc-99m) account for the majority of shares due to its ideal half-life and energy emission properties.

Breakup By Application:

  • Cardiology
  • Oncology
  • Thyroid
  • Neurology
  • Others

Cardiology dominates the market as it needs advanced diagnostic tools for early detection and treatment.

Breakup By End User:

  • Hospitals
  • Diagnostic Centers
  • Specialty Clinics
  • Education and Research Institutes
  • Others

Based on the end user, the market has been divided into hospitals, diagnostic centers, specialty clinics, education and research institutes, and others.

Breakup By Region:

  • Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)
  • North America (United States, Canada)
  • Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
  • Latin America (Brazil, Mexico, Argentina, Colombia, Chile, Peru, Others)
  • Middle East and Africa ( Turkey, Saudi Arabia, Iran, United Arab Emirates, Others)

North America holds the leading position owing to a large market for nuclear medicine radioisotopes driven by its advanced healthcare infrastructure, high adoption of innovative medical technologies, and significant investments in research and development (R&D).

Top Nuclear Medicine Radioisotopes Market Leaders:

The nuclear medicine radioisotopes market research report outlines a detailed analysis of the competitive landscape, offering in-depth profiles of major companies.

Some of the key players in the market are:

  • Bracco S.p.A.
  • Bruce Power Inc.
  • Cardinal Health Inc.
  • China Isotope & Radiation Corporation (China National Nuclear Corporation)
  • Curium Pharma
  • Eckert & Ziegler
  • Nordion (Canada) Inc (Sotera Health Company)
  • NorthStar Medical Radioisotopes, LLC
  • NTP Radioisotopes SOC Ltd.
  • Shine Technologies LLC

Ask Analyst & Browse full report with TOC List of Figures: https://www.imarcgroup.com/request?type=report&id=7532&flag=C

If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.

About Us:

IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services.

IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.

Contact US:

IMARC Group

134 N 4th St. Brooklyn, NY 11249, USA

Email: sales@imarcgroup.com

Tel No:(D) +91 120 433 0800

United States: +1-631-791-1145